Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 3:14:821235.
doi: 10.3389/fnagi.2022.821235. eCollection 2022.

The Association of Pre-existing Diagnoses of Alzheimer's Disease and Parkinson's Disease and Coronavirus Disease 2019 Infection, Severity and Mortality: Results From the Korean National Health Insurance Database

Ji Hee Kim  1 , In Bok Chang  1 , Yoo Hwan Kim  2 , Chan Yang Min  3 , Dae Myoung Yoo  3 , Hyo Geun Choi  3   4
Affiliations

The Association of Pre-existing Diagnoses of Alzheimer's Disease and Parkinson's Disease and Coronavirus Disease 2019 Infection, Severity and Mortality: Results From the Korean National Health Insurance Database

Ji Hee Kim et al. Front Aging Neurosci. .

Abstract

Objectives: Despite the numerous studies on coronavirus disease 2019 (COVID-19), data regarding the impact of pre-existing diagnoses of Alzheimer's disease (AD) and Parkinson's disease (PD) on the susceptibility to and outcome of COVID-19 are limited. We aimed to determine whether patients with AD/PD had a higher likelihood of contracting COVID-19 and experiencing worse outcomes.

Methods: Data from patients with confirmed diagnoses of COVID-19 (n = 8,070) from January to June 2020 and control participants (n = 121,050) who were randomly selected to match the patients on the basis of age and sex were extracted from the Korean National Health Insurance Database. Pre-existing diagnoses of AD and PD were identified based on medical claim codes. The associations of pre-existing AD or PD with contracting COVID-19, developing severe COVID-19 and dying due to COVID-19 were examined using a logistic regression model. The participants' age, sex, income, comorbidity score, and history of hypertension/diabetes were assessed as covariates.

Results: COVID-19 cases were more likely to have a pre-existing AD diagnosis (adjusted odds ratio [aOR] = 2.11, 95% confidence interval [CI] = 1.79-2.50, P-value < 0.001) than controls. COVID-19 cases were more likely to have a pre-existing PD diagnosis than controls, although this estimate did not quite reach statistical significance (aOR = 1.41, 95% CI = 1.00-2.00, P-value = 0.054). Pre-existing AD was related to severe disease and mortality from COVID-19 (aOR = 2.21, 95% CI = 1.64-2.98; aOR = 2.21, 95% CI = 1.00-2.00). Pre-existing PD was not associated with mortality (aOR = 1.54, 95% CI = 0.75-3.16) but was associated with severe disease (aOR = 2.89, 95% CI = 1.56-5.35).

Conclusion: We found that COVID-19 infection was significantly associated with a pre-existing diagnosis of AD but not with a pre-existing diagnosis of PD. Patients with pre-existing AD had higher odds of developing severe COVID-19 and dying. Pre-existing PD was only associated with a higher odds of developing severe COVID-19.

Keywords: Alzheimer’s disease; Coronavirus disease 2019 (COVID-19); Parkinson’s disease; dementia; neurodegeneration; neurodegenerative disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
A flowchart of the screening process used in this study. From a total of 129,120 participants, 8,070 COVID-19 patients were matched for age, sex, and income with 32,280 control participants. AD, Alzheimer’s disease; ICD-10, International Classification of Diseases, Tenth Revision; NHID-COVID DB, National Health Insurance Database Coronavirus disease 2019; PD, Parkinson’s disease; RT-PCR, reverse-transcriptase-polymerase chain reaction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ait Wahmane S., Achbani A., Ouhaz Z., Elatiqi M., Belmouden A., Nejmeddine M. (2020). The possible protective role of α−Synuclein against severe acute respiratory syndrome coronavirus 2 infections in patients with Parkinson’s disease. Mov. Disord. 35 1293–1294. 10.1002/mds.28185 - DOI - PMC - PubMed
    1. Antonini A., Leta V., Teo J., Chaudhuri K. R. (2020). Outcome of Parkinson’s disease patients affected by COVID-19. Mov. Disord. 35 905–908. 10.1002/mds.28104 - DOI - PMC - PubMed
    1. Apio C., Kamruzzaman M., Park T. (2020). Confidence intervals for the COVID-19 neutralizing antibody retention rate in the Korean population. Genomics Inform. 18:e31. 10.5808/GI.2020.18.3.e31 - DOI - PMC - PubMed
    1. Atkins J. L., Masoli J. A., Delgado J., Pilling L. C., Kuo C.-L., Kuchel G. A., et al. (2020). Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort. J. Gerontol.: Ser. A 75 2224–2230. 10.1093/gerona/glaa183 - DOI - PMC - PubMed
    1. Bauer K., Schwarzkopf L., Graessel E., Holle R. (2014). A claims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatrics 14:10. 10.1186/1471-2318-14-10 - DOI - PMC - PubMed

LinkOut - more resources